Parkinson Protein 2, E3 Ubiquitin Protein Ligase (PARK2) antibody

Details for Product No. ABIN271648
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms Park, Prkn
Reactivity
Human
(98), (21), (17), (3), (3), (1), (1)
Host
Rabbit
(82), (14), (13)
Clonality
Polyclonal
Conjugate
Un-conjugated
(1)
Application
Immunohistochemistry (Frozen Sections) (IHC (fro)), Western Blotting (WB)
(91), (54), (38), (24), (11), (9), (8), (6), (2), (2), (1)
Pubmed 6 references available
Catalog no. ABIN271648
Quantity 0.1 mL
Price
Contact our Customer Service for availability and price in your country.
Shipping to United States (Change)
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen A synthetic peptide (NSLIKELHHFRILGEE Q) as part of human Parkin conjugated toKLH.
Specificity This antiserum is known to be highly specific for Parkin shown by IHC and WB. Species Reactivity: Reacts with rat and human. Localization: Accession Number: PRKN2_HUMAN.
Cross-Reactivity Human, Rat (Rattus)
Alternative Name PARK2 / Parkin
Background Parkinson',s disease is a common neurodegenerative disease with complexclinical features. Mutations in the gene, Parkin (PARK2), appear to be responsible forthe pathogenesis of autosomal recessive juvenile Parkinsonism. Parkin plays a role inthe ubiquitin-mediated proteolytic pathway by removal and/or detoxification ofabnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to bethe mechanism underlying pathogenesis of Parkin. Parkin may protect neurons againstalpha synuclein toxicity, proteasomal dysfunction, gpr37 accumulation, andkainate-induced excitotoxicity. It may play a role in controlling neurotransmittertrafficking at the presynaptic terminal and in calcium-dependent exocytosis. Parkin alsoregulates cyclin e during neuronal apoptosis and may represent a tumor suppressorgene. Alternate Names: anti-Ubiquitin E3 ligase PRKN antibody, anti-Parkinson juvenile disease protein 2antibody, anti-Parkinson disease protein 2. GENE NAME: PARK2 antibody, anti-PRKNantibody, biosensis. Related Diseases: Alzheimer's/ Parkinson's
Gene ID 5071, 56816
Application Notes Suggested working dilutions: immunohistochemistry 1:1000,Western Blot 1:2000
Restrictions For Research Use only
Format Liquid
Buffer Reconstitute in 100 ul of sterile water. Centrifuge to remove any insoluble material. Preservative: No Preservative.
Storage 4 °C
General Kitada, Asakawa, Hattori et al.: "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." in: Nature, Vol. 392, Issue 6676, pp. 605-8, 1998 (PubMed).

West, Kapatos, OFarrell et al.: "N-myc regulates parkin expression." in: The Journal of biological chemistry, Vol. 279, Issue 28, pp. 28896-902, 2004 (PubMed).

Wang, Denison, Lai et al.: "Parkin gene alterations in hepatocellular carcinoma." in: Genes, chromosomes & cancer, Vol. 40, Issue 2, pp. 85-96, 2004 (PubMed).

Yao, Gu, Nakamura et al.: "Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 29, pp. 10810-4, 2004 (PubMed).

Pigullo, De Luca, Barone et al.: "Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor." in: Parkinsonism & related disorders, Vol. 10, Issue 6, pp. 357-62, 2004 (PubMed).

Kumru, Santamaria, Tolosa et al.: "Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations." in: Annals of neurology, Vol. 56, Issue 4, pp. 599-603, 2004 (PubMed).

Hosts (82), (14), (13)
Reactivities (98), (21), (17), (3), (3), (1), (1)
Applications (91), (54), (38), (24), (11), (9), (8), (6), (2), (2), (1)
Conjugates (1)
Epitopes (13), (11), (8), (8), (4), (4), (3), (3), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top